Contrasting Pacific Biosciences of California (PACB) & Agilent Technologies (A)
Pacific Biosciences of California (NASDAQ: PACB) and Agilent Technologies (NYSE:A) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.
This is a breakdown of current ratings and recommmendations for Pacific Biosciences of California and Agilent Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pacific Biosciences of California||0||2||1||0||2.33|
Valuation and Earnings
This table compares Pacific Biosciences of California and Agilent Technologies’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pacific Biosciences of California||$90.71 million||3.37||-$74.37 million||($0.91)||-2.89|
|Agilent Technologies||$4.47 billion||5.11||$684.00 million||$2.09||33.87|
Agilent Technologies has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
70.5% of Pacific Biosciences of California shares are owned by institutional investors. 17.8% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Agilent Technologies pays an annual dividend of $0.60 per share and has a dividend yield of 0.8%. Pacific Biosciences of California does not pay a dividend. Agilent Technologies pays out 28.7% of its earnings in the form of a dividend. Pacific Biosciences of California has raised its dividend for 2 consecutive years.
Volatility & Risk
Pacific Biosciences of California has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.
This table compares Pacific Biosciences of California and Agilent Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pacific Biosciences of California||-95.97%||-97.50%||-59.40%|
Agilent Technologies beats Pacific Biosciences of California on 11 of the 17 factors compared between the two stocks.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.
Agilent Technologies Company Profile
Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.